Range tightening and setting lower highThis nasdaq daily top gainer had a run from this morning to the upside. this move is fading and reaching a tightening range or equillibrium and setting a lower high around the .5 fib retracement level and vwap. td9 has printed bull exhastion and ttm has signaled contraction.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.5875 USD
−37.88 M USD
0.00 USD
56.10 M
About GlycoMimetics, Inc.
Sector
Industry
Website
Headquarters
Rockville
Founded
2003
FIGI
BBG001J1BQN9
GlycoMimetics, Inc. is a biotechnology company, which engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
GLYC - Another Nasdaq ShortHere's another Nasdaq stock to short in consideration that there may be a correction coming.
GLYC has printed the SRP shakeout up-down whipsaw that is so often a signal that the trend has changed (as we saw with Bitcoin recently).
Strong bearish RSI divergence since much lower in the uptrend could
5 Hot Biotechs to Hold Over The WeekendMy Post-FDA Over-The-Weekend Watchlist:
$GLYC
$ONCT
$ONCY
$PIRS
$AGEN
All of these biotechs have phase one cancer treatment clinical-trial data releases this weekend. Based on my research, these are the ones that I think are most likely to release good data. Since they are all in phase one, it is
$GLYC Releases Trial Data For Cancer Treatment On The 10thFundamental Analysis:
GlycoMimetics, Inc. is a clinical-stage biotechnology company that focuses on developing glycomimetics that inhibit disease-related functions of carbohydrates. They are currently developing a treatment for hormone receptor-positive metastatic breast cancer . The drug, GMI-13
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of GLYC is 0.2265 USD — it has increased by 2.95% in the past 24 hours. Watch GlycoMimetics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange GlycoMimetics, Inc. stocks are traded under the ticker GLYC.
GLYC stock has risen by 2.95% compared to the previous week, the month change is a −18.23% fall, over the last year GlycoMimetics, Inc. has showed a −88.32% decrease.
GLYC reached its all-time high on Feb 15, 2018 with the price of 26.0500 USD, and its all-time low was 0.1406 USD and was reached on Oct 9, 2024. View more price dynamics on GLYC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GLYC stock is 4.53% volatile and has beta coefficient of 0.20. Track GlycoMimetics, Inc. stock price on the chart and check out the list of the most volatile stocks — is GlycoMimetics, Inc. there?
Today GlycoMimetics, Inc. has the market capitalization of 14.19 M, it has increased by 18.52% over the last week.
Yes, you can track GlycoMimetics, Inc. financials in yearly and quarterly reports right on TradingView.
GlycoMimetics, Inc. is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
GLYC earnings for the last quarter are −0.08 USD per share, whereas the estimation was −0.09 USD resulting in a 11.11% surprise. The estimated earnings for the next quarter are −0.05 USD per share. See more details about GlycoMimetics, Inc. earnings.
GlycoMimetics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
GLYC net income for the last quarter is −7.22 M USD, while the quarter before that showed −9.82 M USD of net income which accounts for 26.48% change. Track more GlycoMimetics, Inc. financial stats to get the full picture.
No, GLYC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 26 employees. See our rating of the largest employees — is GlycoMimetics, Inc. on this list?
Like other stocks, GLYC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GlycoMimetics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GlycoMimetics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GlycoMimetics, Inc. stock shows the sell signal. See more of GlycoMimetics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.